Biotech Values

[genisi]

If a patient fails an anti-TNF agent (there are 5 in the market), doc can either put him on a different anti-TNF agent or switch to a non anti-TNF agent (Actemra, Orencia, Rituxan). Among the latter class (Simponi and Cimzia mentioned in the Sermo Event Report are both anti-TNFs), Orencia has the better efficacy/safety profile and a broader label. BMY also conducts a phase III head-to-head vs. Humira trial to compete in 1st line RA:

http://clinicaltrials.gov/ct2/show/NCT00929864?term=NCT00929864&rank=1